The use of noncarbapenem β-lactams for the treatment of extended-spectrum β-lactamase infections

Pranita Tamma, Jesus Rodriguez-Baňo

Research output: Contribution to journalArticle

Abstract

The continued rise in infections caused by extended-spectrum β-lactamase (ESBL)-producing pathogens is recognized globally as one of the most pressing concerns facing the healthcare community. Carbapenems are widely regarded as the antibiotics of choice for the treatment of ESBL-producing infections, even when in vitro activity to other β-lactams has been demonstrated. However, indiscriminant carbapenem use is not without consequence, and carbapenem overuse has contributed to the emergence of carbapenem-resistant Enterobacteriaceae. The use of non-carbapenem β-lactams for the treatment of ESBL infections has yielded conflicting results. In this review, we discuss the available data for the use of cephamycins, cefepime, piperacillin-tazobactam, ceftolozane-tazobactam, and ceftazidime-avibactam for the treatment of ESBL infections.

Original languageEnglish (US)
Pages (from-to)972-980
Number of pages9
JournalClinical Infectious Diseases
Volume64
Issue number7
DOIs
StatePublished - Apr 1 2017

Keywords

  • Carbapenems
  • Cefepime
  • Cephamycins
  • ESBLs
  • Piperacillin-tazobactam

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Fingerprint Dive into the research topics of 'The use of noncarbapenem β-lactams for the treatment of extended-spectrum β-lactamase infections'. Together they form a unique fingerprint.

  • Cite this